Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: GABA Clear all
Terminated Phase 4 Interventional Results available

Preemptive Analgesia Following Uterine Artery Embolization

NCT01555073
View directory record Official record
Conditions
Uterine Fibroids, Uterine Artery Embolization
Interventions
pregabalin/celecoxib, pregabalin/placebo, celecoxib/placebo, Placebo group
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Pain Associated With Fibromyalgia

NCT02187471
View directory record Official record
Conditions
Pain Associated With Fibromyalgia
Interventions
DS-5565, Pregabalin, Placebo tablet, Placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
91
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 2 Interventional

A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01345045
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-639, pregabalin, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Little Rock, Arkansas • Anaheim, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy

NCT00793910
View directory record Official record
Conditions
Postoperative Pain
Interventions
Gabapentin, placebo
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 4 Interventional Results available

Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures

NCT05076110
View directory record Official record
Conditions
Hip Arthroscopy
Interventions
Oxycodone, Ibuprofen, Gabapentin, Acetaminophen, Methocarbamol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
16 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolism in the Human Brain Following Consumption of a Keto-ester in Alcohol Use Disorder (AUD) With Proton Magnetic Resonance Spectroscopic Imaging (MRSI)

NCT05937893
View directory record Official record
Conditions
BHB Transport, Alcohol Use Disorder
Interventions
Keto-ester followed by Magnetic Resonance Spectroscopic Imaging (MRSI) scans
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 25, 2026, 1:37 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gabapentin in Patients at Clinical Risk for Psychosis

NCT02557945
View directory record Official record
Conditions
Clinical High Risk for Psychosis
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 30 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 2 Interventional Results available

Vigabatrin and Insulin Sensitivity

NCT04321395
View directory record Official record
Conditions
NAFLD, Obesity
Interventions
Vigabatrin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 2 Interventional Results available

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

NCT01262092
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
Interventions
Buprenorphine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction

NCT03818932
View directory record Official record
Conditions
Anterior Cruciate Ligament Injury
Interventions
Celecoxib, Hydrocodone-Acetaminophen, Ketorolac, Gabapentin, Acetaminophen, Diazepam
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 3 Interventional Results available

Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients

NCT01271933
View directory record Official record
Conditions
Fibromyalgia
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
30
States / cities
Orange, California • Santa Ana, California • Ocala, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 1 Interventional

Drug Discrimination in Methadone-Maintained Humans Study 1

NCT00593463
View directory record Official record
Conditions
Drug Dependence
Interventions
Cycloserine, Diltiazem, Gabapentin, Isradipine, Naloxone, Nifedipine, Placebo, Saline, Verapamil
Drug · Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Limited Food Effect Study of Gabapentin 800 mg Tablets

NCT00865631
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin 800 mg tablets, single dose (1 tablet), NEURONTIN® 400 mg capsules, single dose (2 capsules)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 2 Interventional Results available

Pregabalin as Treatment for Alcohol Use Disorder

NCT03256253
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Pregabalin
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Sep 25, 2026, 1:37 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence

NCT00730522
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
CPP-109 vigabatrin, Matching Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Oceanside, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 3 Interventional Results available

Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy

NCT00468845
View directory record Official record
Conditions
Pain, Postoperative
Interventions
pregabalin (Lyrica), matched placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
25 Years to 70 Years · Female only
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
14
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management

NCT02944656
View directory record Official record
Conditions
Pain
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Sep 25, 2026, 1:37 PM EDT
Terminated Phase 2 Interventional Results available

Baclofen Effects on Smoking Urge and Withdrawal

NCT00257894
View directory record Official record
Conditions
Nicotine Use Disorder, Nicotine Dependence, Smoking, Tobacco Use Disorder
Interventions
Baclofen, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Not applicable Interventional

Reduction of Postherpetic Neuralgia in Herpes Zoster

NCT01250561
View directory record Official record
Conditions
Herpes Zoster, Post-herpetic Neuralgia
Interventions
Gabapentin, Valacyclovir
Drug
Lead sponsor
Center for Clinical Studies, Texas
Other
Eligibility
50 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2010 · Synced Sep 25, 2026, 1:37 PM EDT
Not listed Phase 4 Interventional

An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

NCT02633683
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 600 mg
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
11
States / cities
Redwood City, California • San Diego, California • Gulf Breeze, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Plasma Osmolality on Brain Glutamate

NCT00611741
View directory record Official record
Conditions
Schizophrenia
Interventions
furosemide, Na supplements
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 2 Interventional

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders

NCT05064319
View directory record Official record
Conditions
Bipolar Disorder, Cannabis Use, Schizoaffective Disorder, Bipolar Type, Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 25, 2026, 1:37 PM EDT
Completed Phase 3 Interventional

Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy

NCT00027963
View directory record Official record
Conditions
Neurotoxicity, Pain
Interventions
gabapentin, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
22
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2016 · Synced Sep 25, 2026, 1:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

GABA Levels in the Brains of Blind People

NCT00357409
View directory record Official record
Conditions
Vision, Blind
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 25, 2026, 1:37 PM EDT